Catalog No.
EVV03101
Expression system
Mammalian Cells
Species
Human immunodeficiency virus 1
Protein length
Met23-Ile680
Predicted molecular weight
85.10 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q78225
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env
Convergence and divergence of B cell responses in two HIV-1 Env immunizations in Rhesus macaques., PMID:40374902
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost., PMID:40215224
Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge., PMID:40007032
Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study., PMID:39236556
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies., PMID:39235529
Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles., PMID:39046263
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial., PMID:39038477
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial., PMID:38916429
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy., PMID:38782902
CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits., PMID:38605096
Tailoring Tfh profiles enhances antibody persistence to a clade C HIV-1 vaccine in rhesus macaques., PMID:38385642
Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein., PMID:38045703
Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1., PMID:37854587
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US., PMID:37679276
Tailoring Tfh Profiles Enhances Antibody Persistence to a Clade C HIV-1 Vaccine in Rhesus Macaques., PMID:37503150
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study., PMID:36348617
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens., PMID:36179551
V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques., PMID:35935987
Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein., PMID:35882111
Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection., PMID:35848590
Enhanced HIV SOSIP Envelope yields in plants through transient co-expression of peptidyl-prolyl isomerase B and calreticulin chaperones and ER targeting., PMID:35705669
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques., PMID:35585080
A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence., PMID:35503780
HIV-gp140-Specific Antibodies Generated From Indian Long-Term Non-Progressors Mediate Potent ADCC Activity and Effectively Lyse Reactivated HIV Reservoir., PMID:35309295
Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines., PMID:35095862
Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral Attachment., PMID:34896364
HIV-1 Env Does Not Enable the Development of Protective Broadly Neutralizing Antibodies in an Experimental Autoimmune Encephalomyelitis Mouse Model., PMID:34795677
CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques., PMID:34745131
Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure., PMID:34385004
Targeting human langerin promotes HIV-1 specific humoral immune responses., PMID:34324611
AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period., PMID:34229888
Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability., PMID:34199200
Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates., PMID:34099325
Development of a RPLC-UV method for monitoring uncleaved HIV-1 envelope glycoprotein., PMID:33954330
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans., PMID:33859204
Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates., PMID:33723807
[Experience of the National HIV-AIDS Reference Center of Turkey, in the Transition to the New HIV Diagnostic Algorithm; Comparative Analysis of Line-Immunoassay Test and Bio-Rad Geenius™ HIV-1/2 Antibody Confirmatory Assay]., PMID:33590978
A reversed phase HPLC method for the quantification of HIV gp145 glycoprotein levels from cell culture supernatants., PMID:33571843
The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection., PMID:33556148
Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center., PMID:33495459
Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques., PMID:33328567
Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs., PMID:33298954
TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice., PMID:33253297
DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens., PMID:33041100
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study., PMID:33010242
Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques., PMID:33007262
Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor., PMID:32817216
Higher frequencies of functional HIV-envelope-specific memory B cells are associated with nonprogressive HIV infection in Indian population., PMID:32769762
The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection., PMID:32636304
HIV-1 subtype C transmitted founders modulate dendritic cell inflammatory responses., PMID:32615983